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Abstract Nutrients can be classified as either ‘‘essential’’
or ‘‘non-essential,’’ the latter are also termed bioactive
substances. Whereas the absence of essential nutrients from
the diet results in overt deficiency often times with mod-
erate to severe physiological decrements, the absence of
bioactive substances from the diet results in suboptimal
health. Nutrient reference values are set by Codex Ali-
mentarius and regulatory bodies in many countries, mostly
for essential nutrients with recommended daily intakes.
The IOM in the United States has defined a set of four
DRIs that, when data are appropriate, include an EAR, a
RDA that is derived from the EAR, an AI for nutrients
without appropriate data to identify an EAR, and an UL.
From the RDA, the United States derives a labeling value
called the DV, which applies to older children and most
adults. In Codex, the equivalents of the DVs are the NRVs
to be used in calculating percentage values on food labels.
Nothing in the IOM documents specifies that labeling
values can be set only for what have been defined to date as
essential nutrients. Indeed, the US Food and Drug
Administration sets a labeling value for dietary fiber based
on the IOM AI for this ingredient. This conference explores
the definitions, concepts, and data on two of the best
examples of bioactive substances that, perhaps, should
have NRVs: lutein and zeaxanthin, and n-3 long-chain
polyunsaturated fatty acids.
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Background, definitions, and principles
It can be argued that the first official public health dietary
guidance originated with the British Merchant Seaman’s
Act in 1835, which suggested lime or lemon juice for
sailors to prevent what we now know as scurvy. Since then,
guidelines for healthy food patterns have been refined and
are still important nutrition education tools for health
professionals and consumers. Every 5 years (since 1980) in
the United States, the food pattern-based Dietary Guide-
lines for Americans (DGA) are published [1]. In 1941, the
National Research Council released the first set of Rec-
ommended Dietary Allowances (RDAs) for energy, pro-
tein, and eight vitamins and minerals. The RDAs are
quantitative values that are translated to food patterns for
the DGA and many federal food programs and thus began
the nutrient-based guidelines in the United States. The 10th
edition of the RDAs was published in 1989 containing
numerical recommendations for 27 ‘‘essential’’ nutrients
(out of 49 total nutrients).
Beginning in the mid-1990s, the Dietary Reference
Intakes (DRIs) were created by the Food and Nutrition
Board of the US National Academies’ Institute of Medicine
(IOM) to broaden the concept of RDAs beyond ‘‘allevia-
tion of nutrient deficiency diseases’’ to embrace promotion
of good health. The DRIs include RDAs (and Recom-
mended Nutrient Intakes (RNIs) in Canada), as well as
estimated average requirements (EARs), adequate intakes
(AIs), acceptable macronutrient distribution ranges (AM-
DRs), and tolerable upper intake levels (ULs). The amount
of clinical evidence necessary for establishing RDAs is
substantial, and there are well-established procedures for
deriving RDAs. For example, a depletion/repletion trial
with hospitalized human volunteers was the foundation for
the establishment of the EAR, RDA, and UL for vitamin C
[2]. Reference values like RDAs and AIs are used to ensure
sufficient intakes of essential nutrients. Estimation of the
reference range is based, in many cases, on observational
data linked to deficiency symptoms or intakes by healthy
groups. By adding a safety range, it is argued that the
intake will be sufficient and safe.
Foods contain a variety of macronutrients and non-
essential components. Macronutrients can be essential and/
or be oxidized as fuels and provide carbon skeletons and
amino groups for endogenous synthesis of body constitu-
ents. Emerging evidence suggests that both the traditional
essential and some non-essential portions of foods may
provide specific health benefits. As in the case for essential
nutrients, some of the non-essential food components
cannot be made by the body. But if they have health
benefits and are considered to be part of a healthy diet, they
could be considered as bioactive food components. In
contrast to essential nutrients, non-essential bioactive food
components may not have any clearly described clinical
deficiency symptoms when their intake is inadequate.
Vitamins A and C must be obtained from the diet to pre-
vent deficiency diseases, but what about non-provitamin A
producing carotenoids such at lutein and lycopene or the
functionally active long-chain derivatives of essential fatty
acids, such as eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA)? The weight of emerging experi-
mental evidence suggests that these and other food
bioactive substances, including dietary fibers and some
polyphenols, may contribute to health.
In contrast to essential nutrients, it may not be possible
to carry out experiments to prove cause-effect relationships
for non-essential food components. Indeed, studies of
vitamins during the last century resulted in the detection
and identification of these essential compounds. In con-
trast, there are inherent difficulties with constructing
human trials for non-essential food components, whether
provided as pure substances, in foods or from food extracts.
These include lack of validated biomarkers, blinding of test
subjects, and availability of funding for the studies. A
further limitation, especially for bulky ingredients such as
dietary fiber, is the near impossibility of devising a placebo
control. One could argue that more evidence should be
necessary when it comes to making dietary recommenda-
tions for non-essential food components, but the amount of
evidence that might be practically collected may be sub-
stantially less in comparison with that which is expected
for essential nutrients. On the other hand, so-called non-
essential food components may provide health benefits in
ways not yet identified. Epidemiological studies show
some evidence that a diet rich in lutein may be protective
against age-related macular degeneration (AMD). Could it
be that AMD is a symptom of lutein deficiency? Evidence
also exists that indicate a number of dietary components
may have protective effects on multi-factorial lifestyle
diseases such as coronary heart disease (CHD) and cancer,
for example, the cardioprotective effects of a diet rich in
marine-derived n-3 long-chain polyunsaturated fatty acids
(n-3 LCPUFA) or the protective effects against prostate
cancer from a diet rich in tomato products or lycopene.
However, this relationship should not be used to imply that
prostate cancer is a symptom of lycopene deficiency. Thus
far, the decreased risks of AMD, CHD, and prostate cancer
can only be said to be associated with diets rich in lutein,
n-3 LCPUFA or lycopene, respectively. Thus, in the case
of non-essential nutrients, there may be diet related, but not
single nutrient related, ‘‘deficiency’’ disorders, and rec-
ommendations on how to prevent these ‘‘deficiency’’ dis-
orders may be warranted.
Accordingly, a new paradigm that establishes recom-
mendations for non-essential bioactive food components
may be necessary; one that may differ from the traditional
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DRI approach. Some suggest that the ‘‘totality of the evi-
dence’’ should be sufficient to drive public health messages
about non-essential bioactive food components. In this
report, we first review the DRI framework that has been in
place for over 15 years. Second, we address potential
mechanisms for ‘‘accreditation’’ of bioactive food compo-
nents and discuss issues regarding design of studies, risk/
benefit ratios, lack of biomarkers, genetic variability within
the population, challenges in research funding, and the
consequences of the possible negative effects of not taking
any action. Finally, we apply the concept to two examples:
lutein and related compounds, and the n-3 LCPUFAs EPA
and DHA.
The development of nutrient reference values
The long-term goal of developing a new nutrient paradigm
is to provide consumers with appropriate public health
guidance about healthy food choices for both traditional
nutrients and bioactive food components. The Codex
Committee on Nutrition and Foods for Special Dietary
Uses (CCNFSDU) is in the process of developing daily
nutrient reference values (NRVs) for the purpose of
nutrition labeling. The development and sanction of the
NRV should provide protection and reassurance to both the
consumer and the food industry, that is, protection of
the consumer against claims that a product ‘‘contains’’ a
specific ingredient even if the amount is trivial by any
nutritional standard and protection of the food industry by
defining a ‘‘safe harbor’’ for product composition that will
allow effective, truthful, and non-misleading communica-
tion with the consumer. In line with this new concept, the
European Food Safety Authority (EFSA) recently con-
cluded that exposure to ß-carotene from its use as a food
additive and as a food supplement at a level \15 mg/day
does not contribute to adverse health effects in the general
population, including heavy smokers [3].
Emerging data (from in vitro studies, in vivo studies in
animals and some studies in humans) have shown that non-
essential food components may be beneficial to health.
Whether the data can be used to document any causality in
health-related effects of bioactive components needs fur-
ther investigation. The scientific data must demonstrate
consistent results that show that the health impact can be
attributed to the food component of interest. However,
most of the available data are based on observational
studies and consequently on food or dietary patterns con-
taining high or low amounts of a particular bioactive
component. Furthermore, many bioactive components are
‘‘biomarkers’’ for a healthy dietary pattern. Vitamin E is a
good marker for edible plant-derived oils and seedlings,
and zeaxanthin is a biomarker for orange-colored foods
(egg yolk, corn, orange, melon, paprika). As long as we do
not have a clear clinical symptom of an inadequate intake
of a non-essential nutrient, we need to refer to a food or
dietary pattern for a reference value.
The AI is a recommended average daily intake level
based on observed or experimentally determined approxi-
mations or estimates of nutrient intake by a group (or
groups) of apparently healthy people that are assumed to be
adequate in nutrition status. There is nothing in the IOM
definition specifying that the nutrient must be essential to
have an assigned AI value. So-called non-essential nutri-
ents include those oxidized as fuels and those that provide
carbon skeletons and amino groups for endogenous syn-
thesis of body constituents. They can consist of some food
components that may have health benefits and are consid-
ered as part of a healthy diet and may also have a signifi-
cant impact on health.
In the example of fiber (the DRI term ‘‘total fiber’’
means the combination of dietary fibers and functional
fibers), there were enough data demonstrating the potential
health benefits of fibers to establish an AI, but not enough
to establish an EAR, and from it a RDA. A large body of
experimental data acquired since the early 1990s has
demonstrated blood cholesterol lowering effects of dietary
fibers, which has been supported by epidemiological evi-
dence showing correlation between increased intake of
high fiber foods and reduction in risk of CHD. Prospective
cohort studies have suggested that diets high in fiber-rich
foods decrease the risk for hypertension, a risk factor for
CHD. An issue with observational studies examining the
effects of dietary fiber is that it is not possible to distinguish
between the effects of dietary fiber per se and fiber-rich
foods that contain many other food components. Moreover,
foods high in fiber are generally low in fat, saturated fat
and cholesterol, and high in phytochemicals, all of which
are associated with reduced risks of certain chronic dis-
eases. Thus, isolating fiber as a single factor is difficult and
must be evaluated in the context of the total dietary pattern.
Some investigators have specifically analyzed diets for
dietary fiber, and others have used indicators of dietary
fiber intake such as cereals, vegetables, fruits, whole
grains, or legumes. Despite these differences in assessing
fiber intake, the preponderance of the evidence on dietary
fiber and CHD risk based on epidemiological, clinical, and
mechanistic data was strong enough to set a recommended
level of intake (an AI).
In the case of b-carotene and other carotenoids, a DRI
was not established because potential diet-disease effects
could be due to other substances found in carotenoid-rich
foods or to behaviors associated with high fruit and vege-
table consumption, for example, regular physical exercise.
This potential for misattribution illustrates the importance
of understanding the specific role of a nutrient (essential or
Eur J Nutr (2013) 52:1–9 3
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non-essential) in a food matrix or dietary pattern. Large
prospective studies have shown beneficial effects of high
carotenoid containing fruit and vegetable consumption
with respect to chronic diseases. However, the nutrients/
food components responsible for the effects are difficult to
ascertain due to multiple nutrient interactions that would
need to be isolated for study and to the possible substitution
of nutrients known to increase risk for certain chronic
diseases, for example, saturated fats. If a dietary pattern
can be related to a single non-essential nutrient with respect
to a disease risk or disease-related marker, this relationship
may serve as a marker to establish a NRV.
It can be difficult to test the effects of individual food
components on chronic disease risk. Challenges in
obtaining valid, reproducible, and reliable data are
numerous but they need to be overcome. Biomarkers for
health effects should be related to specific diseases as
intermediary endpoints or validated surrogate endpoints of
disease risk. The established disease-related surrogate
endpoints recognized by the US Food and Drug Adminis-
tration (FDA) are few. They are as follows: total/low-
density lipoprotein (LDL) cholesterol, blood pressure for
CHD; polyps for colon/rectal cancer; blood sugar level and
insulin resistance for diabetes; bone mineral density for
osteoporosis; and mild cognitive impairment for dementia.
Large randomized controlled trials (RCTs) play a critical
role in establishing the relationship between intake of
nutrients (essential/non-essential) and risk of chronic dis-
eases; however, is the RCT design appropriate, and indeed
the sole method, to understand the role of whole foods or
food constituents in chronic disease prevention? Finally,
what is the potential harm in making an evidence-based
public health recommendation using data from large pro-
spective cohort studies when there is a lack of large RCTs
versus the potential harm of not making any recommen-
dation at all?
Example: lutein and related compounds
Lutein is a non-provitamin A carotenoid found in green,
leafy vegetables and brightly colored fruits. Zeaxanthin is
also of dietary origin, mainly derived from corn and corn
products. A third related carotenoid, meso-zeaxanthin, is
not normally found in a conventional diet and is generated
in the retina after lutein isomerization [4]. Challenges
inherent in the separation and quantification of meso-zea-
xanthin have resulted in a paucity of data on the content of
this carotenoid in foodstuffs and have rendered the study of
tissue concentrations of this compound problematic. As a
consequence, the few studies that have investigated meso-
zeaxanthin may have been disproportionately influential in
the ongoing debate about its origin.
Lutein, zeaxanthin, and meso-zeaxanthin all accumulate
in the central retina where they are collectively known as
macular pigment (MP) [5]. Lutein and zeaxanthin are
distributed ubiquitously in body tissues, but tend to be
concentrated and the dominant carotenoids in central ner-
vous tissues. Along with meso-zeaxanthin, lutein and
zeaxanthin are the sole MP carotenoids, where they exist in
approximately 500-fold higher concentrations than in other
body tissues. Each of these three compounds exhibits a
regional dominance, with meso-zeaxanthin, lutein, and
zeaxanthin being the dominant carotenoids at the epicenter,
mid-periphery, and periphery of the macula, respectively.
The MP protects the eye from damage due to short wave
length (blue) light and has a strong antioxidant activity.
Indeed, data from animal studies give strong evidence that
the three carotenoids protect photoreceptors against oxi-
dative injury [6]. There is a growing and evidence-based
consensus that MP is important for optimal visual perfor-
mance, because of its blue light-filtering properties and
consequential attenuation of chromatic aberration, veiling
luminance, and blue haze. It has also been hypothesized
that MP may protect against AMD because of the same
optical properties and the antioxidant capacity of the
macular carotenoids.
Carotenoids and visual performance and macular
degeneration
Several studies have shown beneficial effects of carote-
noids on the progression of AMD [7]. The promising data
of the Age-Related Eye Disease Study (AREDS) were
confirmed by a recent Cochrane analysis [8]. The authors
concluded that people with AMD may experience less
progression of the disease as a result of antioxidant vitamin
and mineral supplementation. Based on morphological and
biochemical data, Loughman and colleagues carried out
numerous studies to elucidate which carotenoid is of
greatest importance for the protective effect on AMD [9].
Furthermore, they investigated the effect of carotenoids on
visual performance [10]. The observational study assessed
whether macular pigment optical density (MPOD) is
associated with visual performance. One hundred forty-two
young healthy subjects were recruited. MPOD and visual
performance were assessed by psychophysical tests
including best-corrected visual acuity (BCVA), mesopic
and photopic contrast sensitivity, glare sensitivity, and
photostress recovery time (PRT). Measures of central
visual function, including BCVA and contrast sensitivity,
were found to be positively associated with MPOD
(p \ 0.05, for all).
RCTs have shown that supplementation with carote-
noids (10.6 mg meso-zeaxanthin, 5.9 mg lutein, 1.6 mg
4 Eur J Nutr (2013) 52:1–9
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zeaxanthin) results in an increase in their concentration in
serum as well as in the macula without any adverse effects
on either liver or renal function [11, 12]. Several studies
were performed to elucidate whether one or more carote-
noids detected within the macula are of importance for the
MOPD. Supplementation with carotenoids has been shown
to result in a typical central peak in the MP only in sup-
plements that contain meso-zeaxanthin [9]. In this RCT,
Loughman and colleagues investigated changes in MPOD
and visual performance following supplementation with
different macular carotenoid formulations: (1) 20 mg lutein
and 2 mg zeaxanthin; (2) 10 mg lutein, 2 mg zeaxanthin,
and 10 mg meso-zeaxanthin; and (3) placebo. At 3 and
6 months, a statistically significant increase in MPOD was
found at all eccentricities (other than the most peripheral 3
location) in the group that got all three carotenoids
(P \ 0.05 for all), whereas no significant increase in
MPOD was demonstrable at any eccentricity for subjects
that got only lutein ? zeaxanthin or placebo. Statistically
significant improvements in visual performance measures,
including visual acuity and contrast sensitivity with and
without glare, were also observed only in those who got
meso-zeaxanthin, whereas there was only significant
improved mesopic contrast sensitivity at one spatial fre-
quency by 6 months for the lutein ? zeaxanthin group and
no improvements in any parameters of visual performance
for subjects supplemented with placebo. Thus, these data
show that all three carotenoids are needed to form the
macular pigment. In addition, supplementation has a ben-
eficial effect on visual performance and contrast sensitivity.
The carotenoid intake in this recent study may serve as
reference range with respect to safety and efficacy.
Carotenoids and the brain
Lutein is also the dominant carotenoid in human brain
tissue. While a variety of evidence supports a role for lutein
in eye health, less is available on a relationship between
lutein and cognitive function. From observational studies,
there is evidence that older adults consuming the highest
amounts of green leafy vegetables and cruciferous vege-
tables, which are both rich sources of lutein, had slower
cognitive decline than those consuming the lowest
amounts. Several studies at Tufts University also found that
lutein status is related to better cognitive function in older
adults [13]. A significant relationship was found between
serum levels of lutein and cognitive function in a popula-
tion-based study which looked at biological, psychological,
and social factors that play a role in longevity and survival
of the oldest old [14]. In the Health, Aging, and Body
Composition Study (Health ABC), Renzi and colleagues
found a significant correlation between MP density and the
mini mental state examination, a global measure of cog-
nition [15]. Lutein and zeaxanthin in the eye of rhesus
monkeys have been shown to be significantly related to
lutein and zeaxanthin levels in the brain and MP and can
therefore be used as a biomarker of lutein and zeaxanthin in
primate brain tissue [16]. This finding provides a great
advantage as macular lutein and zeaxanthin can now be
measured by a non-invasive technique. Postmortem lutein
levels in brain tissue have also been found to be signifi-
cantly related to antemortem measures of global cognitive
function, executive function, and dementia severity after
adjusting for age, gender, education, hypertension, and
diabetes [14]. Lastly, in a double-blinded RCT in older
adults supplemented with lutein, alone or in combination
with DHA, Johnson and colleagues reported that verbal
fluency scores improved significantly with the DHA, with
lutein, as well as with the combined treatment groups [17].
Memory scores and rate of learning improved significantly
in the combined treatment group, whose subjects also
displayed a trend toward more efficient learning. These
exploratory findings suggest that lutein supplementation
may have cognitive benefit for older adults. Taking all of
these observations into consideration, the idea that lutein
can influence neural function in older adults is certainly
plausible.
n-3 Long-chain polyunsaturated fatty acids
The n-3 LCPUFAs perform essential functions in the body
in processes such as male reproduction and child devel-
opment. Most experts estimate that the n-3 LCPUFA
requirement is fulfilled at intakes of alpha-linolenic acid
(ALA) from vegetable oils of around 0.5–1 % of the
energy intake. n-3 LCPUFA intake has been shown to
affect health, most notably, the risk of CHD and symptoms
of rheumatoid arthritis as well as infant visual acuity and
atopic risk [18–20]. In addition, n-3 LCPUFA has also been
described to have a potential beneficial impact on other
degenerative diseases, for example, chronic renal diseases,
neurological diseases, and diseases of the eye and the
respiratory tract. These health effects seem to be exerted
mainly by EPA and DHA. The clinical effect of n-3
LCPUFA on rheumatoid arthritis has been shown only at
doses [2.5 g/day, and the effect on visual maturation and
atrophy seems to occur only in the perinatal period [18].
Current evidence indicates that n-3 LCPUFA may also
affect mood, behavior, and overall immune function, but
the evidence does not allow recommendations regarding an
exact dose. There is more convincing evidence on the
quantitative needs in adults to prevent CHD.
With respect to the cardioprotective effects of n-3
LCPUFA, evidence is available from laboratory and
Eur J Nutr (2013) 52:1–9 5
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observational studies, as well as RCTs, with various out-
comes. n-3 LCPUFA has been shown to affect a myriad of
molecular pathways, including alteration of physical and
chemical properties of cellular membranes, direct interac-
tion with and modulation of membrane channels and pro-
teins, regulation of gene expression, and conversion of
n-3 LCPUFA to bioactive metabolites and signalling
molecules, which may all provide plausible biological
explanations for the observed effects. RCTs have shown
that n-3 LCPUFA supplementation in humans lowers
plasma triacylglycerol (TAG), thrombosis, resting heart
rate, and blood pressure and might also improve myocar-
dial filling and efficiency. Additional mechanisms include
lowering inflammation and improving vascular function
while experimental studies demonstrate direct and indirect
antiarrhythmic effects [21]. Observational studies consis-
tently suggest long-term dietary intake of n-3 LCPUFA
from fish has protective effects on cardiovascular disease
when compared with no or very low intake [22]. Large-
scale RCTs in patients with previous myocardial infarction
and heart failure also suggest a significant benefit on car-
diac mortality. However, evidence produced by a recent
RCT of n-3 LCPUFA supplementation to prevent atrial
fibrillation onset or recurrence in patients with diabetes
mellitus who have experienced a myocardial infarction
was, however, disappointing [23]. Differences in experi-
mental clinical settings and methodological limitations of
recent studies make it difficult to interpret these recent
findings. Indeed, data from the recent Alpha Omega Trial
indicate that the effect of n-3 LCPUFA is over-shadowed
by the use of statins [24]. Overall, current data provide
discordant evidence that n-3 LCPUFAs are bioactive
compounds that reduce risk of cardiac death. On the other
hand, sound evidence supports the health benefit of a reg-
ular dietary intake of n-3 LCPUFA, and there is evidence
from RCTs to support the beneficial effects on the men-
tioned cardiovascular risk markers.
Major dietary sources of the n-3 LCPUFA are fatty fish
and other seafood. A meta-analysis of data from 29 pro-
spective cohort studies indicates that maximal CHD pre-
vention occurs at a fish intake of around 50 g/day [21].
Furthermore, a separate meta-analysis calculated that the
incidence of CHD decreases 6 % per 15 g/day increment in
fish intake [25]. The effect on plasma TAG appears to be
linear from 1 to 7 g/day n-3 LCPUFA, whereas the anti-
thrombotic effect requires doses [4 g/day. The effects on
blood pressure and heart rhythm have been shown to occur
within the range of typical dietary intakes and to satiate at
around 0.75–1 g/day. Depending on the fish species, an
intake of 1 g/day n-3 LCPUFA is achievable at daily intakes
of 50 g fish and thus fits well with the observational data.
DHA is the dominant n-3 LCPUFA in tissues, and
although it can be formed endogenously from ALA,
conversion is very low and requires double action of the
key limiting enzyme. Thus, it seems difficult to provide an
ALA-based diet that raises DHA status as effectively as
preformed DHA via the diet, and studies indicate that high
intake of ALA may even lead to a decrease in DHA status.
The combined level of DHA and EPA in erythrocytes (the
Omega-3 Index, X3I) has been proposed as a stable proxy
measure of status and an optimal way to assess need [26].
Research indicates high CHD risk at X3I of\4 %, and the
optimal level appears to be[8 % [27]. To reach an X3I of
8 %, US CHD patients have been shown to require fish oil
supplementation in addition to a fish intake of[2 servings/
week [28]. Tissue n-3 LCPUFA levels are affected by
polymorphism in fatty acid desaturase encoding genes and
by gender, and it may also depend on other dietary aspects.
An X3I of 8 % was found for moderate fish intakes (around
0.6 g/day n-3 LCPUFA) in lactating women, but data also
indicate that daily fish oil supplementation resulted in
higher X3I than a similar habitual intake from fish, indi-
cating that intake frequency may play a role.
Most observational studies and meta-analyses of data
from prospective cohort studies have not been able to show
a beneficial effect of n-3 LCPUFA of vegetable origin.
However, one prospective cohort study found that ALA
intake was associated with reduced CHD risk and the
correlation was most pronounced at n-3 LCPUFA intakes
\0.1 g/day [29]. Furthermore, a recent meta-analysis of
vegetable oil RCTs showed ALA-containing oils reduced
risk, whereas pure linolenic acid (LA) oils increased the
risk of CHD events [30]. It has been suggested that the
need for n-3 LCPUFA is increased by high intake of LA,
but observational studies have not been able to show that
the effect of n-3 LCPUFA is modified by LA intake [29,
31, 32].
There is consensus among numerous authoritative and
regulatory bodies around the world that intake of EPA and
DHA is associated with potential health benefits; however,
there is inconsistent or missing guidance on ULs for these
fatty acids. According to the Codex Guidelines on Nutri-
tion Labelling, the establishment of general population
NRVs should take into account ULs established by rec-
ognized authoritative scientific bodies [33]. Evaluations
from the last couple of years have all concluded that there
is insufficient evidence to establish an UL for n-3 LCPU-
FAs. The following is a brief history on ULs for EPA and
DHA.
• Based on a 1989 report, in 1997, the US FDA declared
that intakes of EPA and DHA from menhaden oil up to
3 g/day are safe for the general population [34]. The
primary reason for the 3 g limit was concern about
bleeding. The authors of the 1989 Mitre Corporation
report wrote, ‘‘An increase in bleeding time is the only
6 Eur J Nutr (2013) 52:1–9
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prominent health effect observed in humans that has
been firmly established as a consequence of fish oil
ingestion. This effect has been reported anecdotally in
the Eskimo population and consistently observed in
studies of healthy human subjects with a daily intake of
3 g of n-3 fatty acids. The magnitude of the effect at
this low dose is not a cause for alarm, but a lack of
systematic dose–response data precludes prediction of
the severity of the effect at higher daily intakes’’ [35].
Note that more recent reports have indicated much
higher levels of n-3 LCPUFA intake without any
bleeding issues.
• In its 2005 report on DRIs for dietary fats, the IOM
indicated that there were insufficient data to support
establishing an UL for EPA and DHA [36].
• In 2009, the German Federal Institute for Risk Assess-
ment (BfR) evaluated EPA and DHA and recom-
mended that no more than 1.5 g/day n-3 LCPUFA from
all sources should be consumed and that food not
typically containing fat (e.g., water-based beverages)
should not be enriched with n-3 LCPUFAs. While
selected studies evaluating several health-based end-
points were summarized in the opinion, the basis for the
limit of 1.5 g/day was not elucidated [37].
• In 2011, the Norwegian Scientific Committee for Food
Safety (VKM) evaluated EPA and DHA and indicated
that it was not possible to identify clear adverse effects
associated with EPA and DHA for the purpose of
setting ULs [38].
• In 2012, EFSA published its scientific opinion related
to ULs for n-3 LCPUFAs with the conclusion that the
available data were insufficient to establish an UL for
n-3 LCPUFAs [39].
• Also in 2012, Spherix Consulting completed its hazard
characterization commissioned by the Global Organi-
zation for EPA and DHA Omega-3s (GOED) including
a range of safety endpoints and adverse effects. No
studies were identified that are appropriate to define
specific intake levels or intake/response relationships
that can be used to define an UL for the investigated
effects [40].
Challenges in establishing upper limits of intake
Originally applied by the IOM to establish ULs, nutrient
risk assessment can be used to identify ULs for bioactive
substances. An important modification to the classic
nutrient risk assessment model is needed, however. By
definition, the establishment of an UL value depends on
the selection of a no observed adverse effect level
(NOAEL) or a lowest observed adverse effect level. For
many bioactive substances (lutein, lycopene, coenzyme
Q10) and some essential nutrients (vitamin B12 and the
amino acids), no hazard has been identified and thus no
NOAEL. Therefore, by definition, an UL cannot be
established for these substances. The absence of an UL
(or some kind of equivalent guidance level to prevent
excessive intakes) has been misinterpreted by some to
mean that little or no safety data exist on these sub-
stances and has led to some overly restrictive and arbi-
trary policies in some countries.
In 2006, the Food and Agriculture Organization/World
Health Organization (FAO/WHO) published the highest
observed intake (HOI) approach to nutrient risk assessment.
Briefly, the HOI approach is used to establish guidance
levels for those nutrients for which no toxicity has been
observed. It involves selection of the highest dose tested
that can be confidently concluded as safe. While the method
has yet to be formally applied, a version of this approach has
been applied and published repeatedly [41–43].
Some of the questions the CCNFSDU has been address-
ing during the eight-step process of establishing NRVs
include: which nutrients should be assigned NRVs, whether
NRVs should be assigned for macronutrients (e.g., protein),
whether there should be more than one NRV per nutrient
(e.g., for specific outcomes), and what data or criteria should
serve as the basis for selection of NRVs. However, to date,
the committee has not fully addressed the critical issue of the
impact of the UL intake on the selection of NRVs. For most
micronutrients and bioactive food components, recom-
mended intake levels (on which the daily NRV is based) fall
far below the UL by several-fold, up to and above an order of
magnitude. However, there are examples from individual
countries (e.g., the United States, Canada) in which the
authoritative body, such as the IOM, has established a RDA
that is perilously close to (in the case of zinc for children) or
even exceeds (in the case of magnesium in children) the UL.
If used as a basis for Codex NRVs, whether for nutrients or
bioactive substances, such policy has the potential to cause
widespread confusion (as it has in individual countries)
among nutrition policy makers and regulators charged with
establishing regulatory maximums.
It is therefore critical that ULs (or HOIs observed) for
essential micronutrients and bioactive food components be
established based on risk assessment, and that these values
be given due account when establishing NRVs, to avoid as
much as possible the scenario of a NRV being too close or
exceeding the UL. Establishing the UL or HOI prior to the
NRV can give policy makers added comfort that the chosen
values for labeling are also safe for the general population,
and it can also help facilitate necessary research on the
benefits of higher intakes of these substances, since it
provides practical guidance for both researchers and insti-
tutional review boards.
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